These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20959117)

  • 1. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
    Fan JR; Huang TH; Wen CY; Shen TL; Li TK
    Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
    Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delphinidin modulates the DNA-damaging properties of topoisomerase II poisons.
    Esselen M; Fritz J; Hutter M; Marko D
    Chem Res Toxicol; 2009 Mar; 22(3):554-64. PubMed ID: 19182879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
    Bau JT; Kang Z; Austin CA; Kurz EU
    Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
    Wartlick F; Bopp A; Henninger C; Fritz G
    Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species.
    Kurz EU; Douglas P; Lees-Miller SP
    J Biol Chem; 2004 Dec; 279(51):53272-81. PubMed ID: 15489221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR.
    Théard D; Coisy M; Ducommun B; Concannon P; Darbon JM
    Biochem Biophys Res Commun; 2001 Dec; 289(5):1199-204. PubMed ID: 11741320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
    Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
    Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of reactive oxygen species, ERK1/2, and p38MAPK in sodium salicylate-induced heat shock protein 72 expression in C6 glioma cells.
    Seo MS; Oh SY; Park MJ; Kim SM; Kim MY; Han SI; Park HG; Kang HS
    Int J Mol Med; 2005 Nov; 16(5):841-9. PubMed ID: 16211253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
    Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
    Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.